A U.S. Patent Application for “End-to-End Cell Therapy Automation” was published by Lonza on June 6th, 2019. The present invention is a method for automated production of a genetically modified immune cell culture, the method comprising: (a) activating an immune cell culture with an activation reagent to produce an activated immune cell culture; (b) transducing the activated immune cell culture with a vector, to produce a transduced immune cell culture; (c) expanding the transduced immune cell culture; (d) concentrating the expanded immune cell culture of (c); and (e) harvesting the concentrated immune cell culture of (d)… Learn More